Azithromycin and other macrolides for prevention of bronchopulmonary dysplasia: A systematic review and meta-analysis

Neonatology

Volumn 106, Issue 4, 2014, Pages 337-347

  Nair, Vrinda ^a   Loganathan, Prakash ^a   Soraisham, Amuchou Singh ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b ALBERTA CHILDREN'S HOSPITAL   (Canada)

Author keywords

Azithromycin; Bronchopulmonary dysplasia; Macrolides; Preterm infants

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE; PLACEBO; ROXITHROMYCIN; TROLEANDOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ASSISTED VENTILATION; HUMAN; INCIDENCE; INFANT; INFANT MORTALITY; LUNG DYSPLASIA; META ANALYSIS; NONHUMAN; OUTCOME ASSESSMENT; PREMATURITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; UREAPLASMA; BRONCHOPULMONARY DYSPLASIA; CHI SQUARE DISTRIBUTION; GESTATIONAL AGE; MORTALITY; NEWBORN; RISK; RISK FACTOR; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BRONCHOPULMONARY DYSPLASIA; CHI-SQUARE DISTRIBUTION; GESTATIONAL AGE; HUMANS; INFANT; INFANT MORTALITY; INFANT, NEWBORN; INFANT, PREMATURE; ODDS RATIO; RISK FACTORS; TREATMENT OUTCOME;

EID: 84910650229     PISSN: 16617800     EISSN: 16617819     Source Type: Journal    
DOI: 10.1159/000363493     Document Type: Review

References (37)

1. Schmidt B, Asztalos EV, Roberts RS, et al: Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms. JAMA 2003;289:1124-1129.
2. Ehrenkranz RA, Walsh MC, Vohr BR, et al: Validation of the national institutes of health consensus definition of bronchopulmonary dysplasia. Pediatrics 2005;116:1353-1360.
3. Speer CP: Chorioamnionitis, postnatal factors and proinflammatory response in the pathogenetic sequence of bronchopulmonary dysplasia. Neonatology 2009;95:353-361.
4. Goldenberg RL, Andrews WW, Goepfert AR et al: The Alabama Preterm Birth Study: Umbilical cord blood Ureaplasma urealyticum and Mycoplasma hominis cultures in very preterm newborn infants. Am J Obstet Gynecol 2008;198:43.e1-43.e5.
5. Collins JJP, Kallapur SG, Knox CL, et al: Repeated intrauterine exposures to inflammatory stimuli attenuated transforming growth factor-β signaling in the ovine fetal lung. Neonatology 2013;104:49-55.
6. Kotecha S, Hodge R, Schaber JA, Miralles R, Silverman M, Grant WD: Pulmonary Ureaplasma urealyticum is associated with the development of acute lung inflammation and chronic lung disease in preterm infants. Pediatr Res 2004;55:61-68.
7. Wang EE, Ohlsson A, Kellner JD: Association of Ureaplasma urealyticum colonization with chronic lung disease of prematurity: results of a metaanalysis. J Pediatr 1995;127:640-644.
8. Schelonka RL, Katz B, Waites KB, Benjamin DK Jr: Critical appraisal of the role of Ureaplasma in the development of bronchopulmonary dysplasia with meta-analytic techniques. Pediatr Infect Dis J 2005;24:1033-1039.
9. Gravett MG, Novy MJ, Rosenfeld RG, et al: Diagnosis of intra-amniotic infection by proteomic profiling and identification of novel biomarkers. JAMA 2004;292:462-469.
10. Moss TJ, Knox CL, Kallapur SG, et al: Experimental amniotic fluid infection in sheep: effects of Ureaplasma parvum serovars 3 and 6 on preterm or term fetal sheep. Am J Obstet Gynecol 2008;198:122.e1-122.e8.
11. Li YH, Brauner A, Jonsson B, et al: Ureaplasma urealyticum-induced production of proinflammatory cytokines by macrophages. Pediatr Res 2000;48:114-119.
12. Li YH, Chen M, Brauner A, Zheng C, Skov Jensen J, Tullus K: Ureaplasma urealyticum induces apoptosis in human lung epithelial cells and macrophages. Biol Neonate 2002;82:166-173.
13. Ozdemir R, Sari FN, Tunay ZO, et al: The association between respiratory tract Ureaplasma urealyticum colonization and severe retinopathy of prematurity in preterm infants
14. Kasper DC, Mechtler TP, Bohm J, et al: In utero exposure to Ureaplasma spp. is associated with increased rate of bronchopulmonary dysplasia and intraventricular hemorrhage in preterm infants. J Perinat Med 2011;39:331-336.
15. Viscardi RM, Hashmi N, Gross GW, Sun CC, Rodriguez A, Fairchild KD: Incidence of invasive Ureaplasma in VLBW infants: relationship to severe intraventricular hemorrhage. J Perinatol 2008;28:759-765.
16. Okogbule-Wonodi AC, Gross GW, Sun CC, et al: Necrotizing enterocolitis is associated with Ureaplasma colonization in preterm infants. Pediatr Res 2011;69:442-447.
17. Berger A, Witt A, Haiden N, et al: Intrauterine infection with Ureaplasma species is associated with adverse neuromotor outcome at 1 and 2 years adjusted age in preterm infants. J Perinat Med 2009;37:72-78.
18. Jaffe A, Bush A: Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 2001;31:464-473.
19. Aghai ZH, Kode A, Saslow JG, et al: Azithromycin suppresses activation of nuclear factor-kappa B and synthesis of pro-inflammatory cytokines in tracheal aspirate cells from premature infants. Pediatr Res 2007;62:483-488.
20. Lyon AJ, McColm J, Middlemist L, Fergusson S, McIntosh N, Ross PW: Randomized trial of erythromycin on the development of chronic lung disease in preterm infants. Arch Dis Child Fetal Neonatal Ed 1998;78:F10-F14.
21. Jonsson B, Rylander M, Faxelius G: Ureaplasma urealyticum, erythromycin and respiratory morbidity in high-risk preterm neonates. Acta Paediatr 1998;87:1079-1084.
22. Ballard HO, Anstead MI, Shook LA: Azithromycin in the extremely low birth weight infant for the prevention of bronchopulmonary dysplasia: a pilot study. Respir Res 2007;8:41.
23. Ballard HO, Shook LA, Bernard P, et al: Use of azithromycin for the prevention of bronchopulmonary dysplasia in preterm infants: a randomized, double-blind, placebo controlled trial. Pediatr Pulmonol 2011;46:111-118.
24. Gharehbaghi MM, Peirovifar A, Ghojazadeh M, Mahallei M: Efficacy of azithromycin for prevention of bronchopulmonary dysplasia (BPD). Turk J Med Sci 2012;42:1070-1075.
25. Ozdemir R, Erdeve O, Dizdar EA, et al: Clarithromycin in preventing bronchopulmonary dysplasia in Ureaplasma urealyticum-positive preterm infants. Pediatrics 2011;128:e1496-e1501.
26. Mabanta CG, Pryhuber GS, Weinberg GA, Phelps DL: Erythromycin for the prevention of chronic lung disease in intubated preterm infants at risk for, or colonized or infected with Ureaplasma urealyticum. Cochrane Database Syst Rev 2003; CD003744.
27. Abele-Horn M, Becher C, Bauernfeind A, et al: Comparative in vitro susceptibility of Ureaplasma urealyticum and Mycoplasma hominis to macrolides, tetracyclines, 4-quinolones, chloramphenicol, gentamicin, and clindamycin. Antiinfect Drugs Chemother 1996;14:171-173.
28. Togami K, Chono S, Morimoto K: Distribution characteristics of clarithromycin and azithromycin, macrolide antimicrobial agents used for treatment of respiratory infections, in lung epithelial lining fluid and alveolar macrophages. Biopharm Drug Dispos 2011;32:389-397.
29. Gutierrez-Castrellon P, Mayorga-Buitron JL, Bosch-Canto V, Solomon-Santibanez G, De Colsa-Ranero A: Efficacy and safety of clarithromycin in pediatric patients with upper respiratory infections: a systematic review with meta-analysis. Rev Invest Clin 2012;64:126-135.
30. Waites KB, Crouse DT, Cassell GH: Antibiotic susceptibilities and therapeutic options for Ureaplasma urealyticum infections in neonates. Pediatr Infect Dis J 1992;11:23-29.
31. Hassan HE, Othman AA, Eddington ND, Duffy L, Xiao L, Waites KB, et al: Pharmacokinetics, safety, and biologic effects of azithromycin in extremely preterm infants at risk for Ureaplasma colonization and bronchopulmonary dysplasia. J Clin Pharmacol 2011;51:1264-1275.
32. Samra Z, Rosenberg S, Dan M: Susceptibility of Ureaplasma urealyticum to tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin. J Chemother 2011;23:77-79.
33. Kenyon S, Boulvain M, Neilson JP: Antibiotics for preterm rupture of membranes. Cochrane Database Syst Rev 2013; CD001058.
34. Cotton CM, Taylor S, Stoll B, et al: Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. Pediatrics 2009;123:58-66.
35. Abo-Salem E, Fowler JC, Attari M, Cox CD, Perez-Verdia A, Panikkath R, Nugent K: Antibiotic-induced cardiac arrhythmias. Cardiovasc Ther 2014;32:19-25.
36. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM: Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366:1881-1890.
37. Lund M, Pasternak B, Davidsen RB, et al: Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort study. BMJ 2014;348:1-10.